0·52-0·93). Moreover, the secondary outcome of vascular mortality (0·80, 0·56-1·16) showed a similar result when deaths due to haemorrhage or unknown causes were removed (0·79, 0·50-1·26). The authors highlighted our work on the development of the fragility index (ie, the minimum number of patients from the treatment group with fewer events who would have to switch from a nonevent to an event to reverse statistical significance).
3 The lower a fragility index, the more fragile a result. The authors are correct that the fragility index is 7 for the primary outcome in the MANAGE trial; however, a fragility index of 7 is not low. Similar to a p value, there is no optimal threshold for the fragility index; however, some authors have used a fragility index of 3 or lower to represent fragile trial results. 4 The median time from randomisation until the patients had permanently discontinued the study drug was 95 days in the dabigatran group and 50 days in the placebo group.
Samuel Benham-Mirando states that comparison of an anticoagulant such as dabigatran with placebo is not as useful as a comparison with the current recommended management strategy for myocardial injury after non-cardiac surgery, which is aspirin and a statin. During follow-up, 74% of the patients in the placebo group took an antiplatelet drug, 69% took a statin, and 8% took a dual antiplatelet drug. We show that echocardiography was the most common (23%) type of cardiac testing ordered by physicians related to the qualifying myocardial injury after noncardiac surgery.
1 To us, an important inference from the trial is that all patients with myocardial injury after non-cardiac surgery should be offered aspirin and a statin. Because of the high proportion of patients receiving these drugs in our trial, the evidence provides support for dabigatran to be taken in addition to aspirin and a statin.
We declare no competing interests. 
Authors' reply
Wilton A van Klei and colleagues erroneously state that there were posthoc changes in the outcomes in our Article. 1 The only changes that were made in the outcomes were done during the trial, without knowledge of the trial results. We added amputation and symptomatic proximal deep-vein thrombosis to the primary composite outcome to enhance trial power, and because the COMPASS trial 2 showed that an oral direct anticoagulant reduced the risk of these outcomes in patients with vascular disease. Dabigatran not only showed a significant reduction in our primary outcome of a major vascular complication (hazard ratio [HR] 0·72, 95% CI 0·55-0·93), but also significantly reduced the original composite outcome (ie, vascular mortality and non-fatal myocardial infarction, stroke, peripheral arterial thrombosis, and symptomatic pulmonary embolism; 0·74, 0·56-0·99).
Van Klei and colleagues have requested a post-hoc change to not include haemorrhagic and unknown causes of death in the vascular death category. Even with this change, dabigatran still showed a significant reduction in major vascular complications (HR 0·70, 95% CI Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019; 393: 229-40 Article, ten neonatal deaths (eight in the progesterone and two in the control group) were incorrectly categorised as postneonatal deaths, with no effect on the primary outcome and study conclusions. These corrections have been made online as of Jan 17, 2019, and the supplementary appendix of this Article has also been corrected as of Jan 17, 2019.
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